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ABSTRACT
Software systems are becoming increasingly complex. Within
safety critical domains such as medical device software, this
increasing complexity is placing growing demands on
manufacturers who must ensure their software not only meets
functional requirements but is also safe and reliable. However, the
Food and Drugs Administration who regulate medical device
software in the United States report a significant increase in
recalls between years 2003 and 2012 and have cited software
difficulties as one of the frequent causes of recalls. Furthermore a
recent analysis of traceability documentation submitted to the
Administration has revealed that the traceability data was
incomplete, incorrect, and conflicting in many cases. This is
problematic as traceability plays an important role in the
development of safe and reliable software. In this paper we
present the validation, through industry trial, of a traceability
assessment and implementation framework which we have
developed to assist medical device organizations implement
traceability in an efficient and regulatory compliant manner. Our
findings show that implementation of the framework within two
organizations improved their traceability process and that both
organizations found the framework to be both useful and usable.
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1. INTRODUCTION
Traceability, which is the ability to establish and use the links (or
traces) between source artefacts and target artefacts [7].
Traceability is important as developers need to ensure that their
software conforms to customer expectations, functional and
regulatory requirements. Additionally, traceability is important for
impact analysis as it assists developers to visualize how a change
in any component can affect the software system. Therefore an
effective traceability process supports the development of quality
software and reduces the possibility of delays, recalls, or even
complete project failures. Despite this traceability is problematic
as ‘most existing software systems lack explicit traceability links
between artefacts’ [8].
Organizations that produce safety critical software must ensure
their software is safe, reliable and available. Safety critical
software can be described as software, which if fails could cause
damage to the environment, injury or death [22]. Within the safety
critical medical device domain, medical devices must frequently
interface with other equipment, connect to hospital and laboratory
information systems, and work in high-stress situations. The
increased demands on such devices has resulted in increased
software complexity and has created formidable development
challenges for their manufacturers [13]. A medical device can be
described as any article intended for use in the diagnosis, care,
treatment or prevention of disease that does not achieve its
intended purpose by medicines [6]. A recent report by the United
States Food and Drugs Administration (FDA) finds that the
annual number of medical device recalls increased by 97 percent
(from 600 to 1200) between years 2003 and 2012 and lists
software difficulties as one of the most frequent causes of recall
[3]. An analysis of medical device recalls in the EU reports
similar figures to that of the United States [2], indicating a
growing and significant problem. As in other domains, traceability
implementation within the medical device domain is challenging
and has been highlighted by a recent analysis of the traceability
documents submitted to regulators in the United States as part of
the medical device approval process. This analysis has revealed
that the traceability data was incomplete, incorrect, and
conflicting in many cases [1].
To determine the challenges to implementing traceability
effectively, the authors conducted a literature review in addition
to interviewing two medical device organizations [14, 17]. As a
result a number of challenges were identified including a lack of
guidance on what traceability to implement and how to implement
it. To assist medical device organizations overcome this
challenge the authors have developed a traceability assessment
and implementation framework (TAIF). The framework consists
of a traceability assessment model (TAM) and a traceability
roadmap (TR). The TAM identifies any gaps in an organizations
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implementation of traceability best practices [18] and/or medical
device standards’ traceability requirements[19], and the TR
provides the pathway for an organization to plug those gaps. An
initial validation of the TAIF was completed through expert
review [15, 16]. Further validation of the model has been
completed through its implementation in two medical device
organizations. In this paper we present the results of that
implementation and evaluate the ability of the TAIF to assist
medical device software organizations implement effective
traceability and put them on the path to regulatory compliance.
The remainder of this paper is structured as follows: Section 2,
outlines current assessment models’ relationship to traceability.
Section 3 outlines the methodology used to evaluate the roadmap
while Section 4 presents the results of the evaluation. Section 5
provides for a discussion of the results while Section 6 concludes
the paper.
2. RELATED WORK
A literature review was conducted by the authors to determine
what other traceability assessment models or traceability
roadmaps were available in the general, safety critical or medical
device domains.
2.1 Roadmaps
A Framework for Requirements Traceability [12] has been
proposed which provides guidelines to assist with implementing
traceability. This framework advocates the use of ‘Value Based
Requirements Tracing’ which may not be an option if full tracing
is a requirement of the customer or the medical device
development process standards. Additionally this framework does
not fulfil the requirements of a traceability implementation
roadmap as defined in the introduction to this paper.
‘Software Traceability: A Roadmap’ [23] presents a roadmap of
research and practices related to software traceability and identify
issues that are still open for further research. While this paper
does highlight barriers to implementing traceability (and areas for
further research) it does not provide a traceability implementation
roadmap.
A number of medical device standards implementation roadmaps
have been developed [4, 5]. These roadmaps provide a pathway
for medical device organizations to implement particular medical
device standards for risk management, usability design, and
quality management. However these roadmaps only provide
traceability requirements from any one standard and there is no
detail on how these requirements might be achieved.
2.2 Traceability Assessment
To assist organizations to improve their traceability researchers
have published work on the assessment of traceability. Med-trace
[10] is a lightweight traceability assessment method (containing 8
stages) to assist medical device organizations to improve their
software development traceability process. However, this
assessment method is ‘lightweight’ in nature (as described by the
authors), does not assess any of the best practices for
implementing traceability, and its development was not based on
any recognized international standard e.g. ISO 15504 [9].
An approach to automate the assessment of traceability has been
presented in response to ‘the gap between what is described by
guidelines and what is implemented in practice’ [20]. This
approach, which is not specific to any particular domain, involves
automatically parsing project data to capture trace information.
While this approach automatically assesses the standards’
requirements for traceability it does not assess the implementation
of traceability best practices.
There are a number of process assessment models which provide
common frameworks for assessing software process capability.
These models include ISO/IEC 15504 SPICE, Automotive
SPICE [14], SPICE 4 SPACE [15], and CMMI [21]. These
frameworks assess processes such as the software design process,
software construction process, software testing process etc.
However, the frameworks do not include a dedicated traceability
assessment process. The frameworks do include elements of
traceability assessment but it is spread out across a lot of
processes and the traceability requirements are sometimes difficult
to interpret.
3. INDUSTRY VALIDATION
In order to meet the aim of this study which is the evaluation of
the TAIF, a longitudinal study of two medical device
organizations was performed over a six month period. For the
study the Adept process appraisal method [11] was employed as it
could provide a comprehensive assessment of an organizations’
traceability compliance without being too onerous in terms of
resources that the organization need to provide.
An initial assessment was conducted in both organisations using
the TAM which highlighted areas for improvement. A findings
report was delivered to the organisation along with the TR which
provided a pathway for the organisations to improve their
traceability. A follow up assessment conducted six months later
(again using the TAM) indicated what improvements were made.
Additionally, after this follow up assessment, two representatives
from each organization were interviewed about their experience of
using the TAIF and how beneficial they found it to be. The
interviews were semi-structured in nature as this provided a means
to address any issues or points that may arise during the interview
that may not have been predicted during the generation of the
questions. The interview questionnaire was divided into two main
parts. Part A examined the value and usefulness of the assessment
experience to the organization. Part B examined the usefulness
and usability of the roadmap in implementing the
recommendations that had resulted from the initial assessment.
3.1 Participants
Organization ‘A’ is a small medical device software company,
founded in 2002, based in Ireland. The company has a total of ten
employees which include one programmer, one software tester
and one quality assurance person. The company produces medical
device software with a software safety classification of B,
meaning non-serious injury is possible.
Organization ‘B’ is a small Product Development & Design
Engineering company focused on the Medical Device and Life
Science market and is based in Ireland. The company, which was
formed in 2007, employs 14 individuals with skills in mechanical,
hardware and software engineering. The company are a third party
supplier of software to medical device companies and have
recently been accredited with IEC 62304 certification.
4. RESULTS
The results of the initial traceability implementation assessment
and follow up assessment are presented in section 4.1. Section 4.2
presents the results of evaluating the assessment experience while
section 4.3 presents the results of the roadmap evaluation. The
data presented in section 5.1 was collected through document
analysis and interviews as part of the Adept method while the data
presented in section 5.2 and 5.3 was collected through interviews.
4.1 Processes Assessment
The results of the initial assessment and final assessment are
presented in tabular format in Table 1 and for the purpose of
clarity the results are also presented as percentages in Table 2.
Table 1. Best Practices and Traceability Links
Implementation- Initial and Final Assessment
Initial
Assess
Best Practices and Trace Links Not
Implemented
Final
Assess
Best Practices
Company policy on traceability
Traceability improvement communication method B
Traceability Information Model
Traceability standard operating procedure
Resources to implement traceability unavailable B
Appropriate techniques not deployed B
Risk Management Traceability Requirement
Link hazardous situation to software item B
Link software item to software cause
B Link software cause to risk control measure B
B Link RCM to risk control verification A,B
B Link Hazard to assessment of residual risk B
SDLC Traceability Requirement
B Link software req. to system req. and their source A,B
Link software req. to source code (where required)
B Link soft. arch. design to soft. detailed design B
B Link soft. detailed design to source code B
B Link soft arch. design to test A,B
B Link soft detailed design to test B
B Link source code to test B
Change Management Traceability Requirement
B Link change request to problem report A,B
Table 1, presents the traceability best practices and traceability
requirements that were not implemented by either organisation
‘A’ or ‘B’ during the initial assessment (Column 1.) and during
the final assessment (Column 3). For example, both organizations
‘A’ and ‘B’ had no traceability improvement communication
method in place at the initial assessment. However, at the final
assessment organisation ‘B’ had met this requirement. This means
that organisation ‘B’ implemented a traceability improvement
communication method between the initial and the final
assessments while organisation A had not. Table 2 indicates the
percentage achievement of the outcomes for each process. For
example, organisation ‘A’ had fully achieved three (or 75%) of
the outcomes in the initial assessment and in the final assessment
they had fully achieved all four outcomes (i.e. 100%). As
indicated in Table 1 the purpose of this outcome is to implement
traceability between each change request and the problem report
ID from which it originated. The organization achieved this by
adding a ‘source of change request’ section to their change control
form.
Table 2. Results of Initial Assessment and Final Assessment
Best Pract. SDLC Trac RM Trac CM Trac
Init. Final Init. Final Init. Final Init. Final
Org. A 5% 5% 22% 44% 40% 53% 75% 100%
Org. B 10% 41% 89% 89% 75% 88% 100% 100%
The results indicate an improvement in all processes except for
organization A’s Best Practice process which remained at 5% of
full implementation and organization B’s SDLC process and CM
process (which had already been 100% complete).
4.2 Evaluation of the Assessment Experience
To fully evaluate the TAIF it was necessary to appraise the
participating organizations experience of undergoing the
assessment. Therefore, questions were formulated to ascertain the
participating organizations perspective with regard to the value
and usefulness of the assessment to the organizations.
Within the assessment, all questions asked the users to respond
using a five point Likert scale. In some cases answers ranged from
strongly disagree (1) to strongly agree (5), or very bad (1) to very
good (5). Additionally, the organizations were asked to provide a
rationale for their decision.
4.2.1 Value of Assessment
With regard to the value of the assessment, questions were asked
during the final assessment to determine:
a) The organization’s understanding of the assessment process
and its results;
b) The organization’s understanding of the purpose of the
activities that took place as part of the assessment;
c) The organization’s perspective on whether the assessment
was worth the time and effort expended?
d) The organization’s view on how good or bad the assessment
results characterize their traceability strength or weaknesses.
The results are presented in Figure 4.
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Figure 4. Value of Assessment
As an example, in response to a question on whether the
assessment was worth the time and effort expended, organization
‘A’ responded with a ‘4’ and provided the following rationale:
“Our organization did not have the knowledge or the expertise
required. The assessment identified many areas that current
practice was lacking. Extensive knowledge and experience would
be required to produce the quality of report provided by the
assessment….very few people would have this”
4.2.2 Usefulness of assessment
To evaluate the usefulness of the assessment, questions were
formulated to determine the organization’s viewpoints with
regards to:
a) How the assessment helped us better understand what needs
to be improved with regards to traceability?
b) If the assessment improved awareness, buy-in and support
for traceability within our organization;
c) If the assessment model provides real direction for long
term traceability improvement?
The results are presented in Figure 5.
Figure 5. Usefulness of Assessment
As an example, in response to a question on how much the
assessment helped the organization better understand what needs
to be traced, organization ‘B’ returned a ‘5’ and provided the
following rationale: “We are definitely much more aware of what
needs to be traced. Although we were aware that traceability was
a requirement of the standards we obviously weren’t aware of
how much was required. The assessment has highlighted our
deficiencies and as we are a small organization everyone is now
very aware”.
4.3 Evaluation of the Roadmap
To evaluate the roadmap, questions were formulated to determine
the participating organization’s perspective of the roadmap with
regard to its usefulness and usability. These questions assessed
their agreement with:
a) The overview section is easy to understand;
b) The correctness of the order of implementation as depicted
in Overview section;
c) The roadmap is useful in practice;
d) The roadmap is usable in practice;
e) The roadmap provides sufficient guidance.
The results are presented in Figure 6.
Figure 6. Roadmap - Usefulness and Usability
As an example, in response to a question on how much they
agreed that the roadmap provides sufficient guidance on how to
go about improving traceability, organization ‘B’ scored this
category with a ‘5’ and provided the following rationale: “The
roadmap is comprehensive. It explains what you have to do and is
not difficult to comprehend.”
In addition to the above, a number of questions were asked to
determine the organization’s viewpoint with regard to any
deficiency they have observed with the roadmap, any suggestions
they have for improvement, or what they thought were the major
benefits of the roadmap. Organization ‘A’ suggested that it might
help if the best practices could be prioritized, with ‘Resources’ as
first best practice. The major benefit of the roadmap as far as
organization ‘A’ was concerned was that ‘it provided them with
an expertise that was not available within the organization and
that they do not believe many organizations would have such a
wealth of knowledge on the subject’. The fact that the roadmap
detailed all the medical device traceability requirements was a
major benefit for organization ‘B’ as they felt that the standards
can be difficult to interpret. As an example of the usefulness and
usability of the roadmap organization ‘A’ stated that for the CM
process they were easily able to link change request to problem
report as “Method B in Appendix C of the roadmap clearly
defined how we could easily do this simply by adding a source of
change request section to the change request form”.
5. DISCUSSION
The inadequate implementation of the best practice process in
both organizations is clearly evident in Table 1. Organization ‘A’
indicated that the reason for this was that they were simply
unaware of the best practices and did not have any expertise in
this area. Additionally, the reason that they showed no
improvement in this area was that they focused their resources
towards the other three processes for two reasons: the SDLC, RM
and CM processes contained ‘regulatory requirements’ whereas
the best practice process did not; their resources were particularly
limited during this time period with some personnel leaving the
organization and not yet been replaced. Organization ‘A’ has
indicated that they wish to achieve 100% implementation across
all four processes but with their very limited resources they were
not able to indicate when this would happen. While the results
from organization ‘B’ indicated a marked improvement in their
implementation of the best practices process they are acutely
aware that they still have significant work to do in this area. They
have indicated that the reason why further improvement has not
been achieved is one of resources. However, organization ‘B’ has
set itself a goal of achieving 100% implementation across the four
process areas and to this extent a new person has been hired with
part of his remit being to work towards this goal.
The results of the evaluation of the assessment experience have
been very positive as indicated in Figures 4 and 5. Figure 4 point
b indicates that organization ‘A’ could have had a better
understanding of the purpose of the activities that took place
during the assessment. While Step 2 of the Adept method requires
the assessment process be explained to staff prior to the
assessment, for future assessments a more detailed explanation of
the process will be delivered at Step 2. However it is believed that
this did not have any effect on the results of the assessment.
Another area noted for improvement is that the assessment report
could better characterize the organizations traceability strong
points, with organization ‘A’ stating: “although the assessment
did expose many areas that we are not covering in current TM
template, we are compliant in some areas which maybe could be
more evident in the report”.
While the evaluation of the assessment process has highlighted
areas for improvement, the lightweight nature of the assessment
was noted as a major benefit with organization ‘B’ stating: “it was
good that the assessment interviews were done in less than 1.5
hours as time is a limited resource in this organization”.
With regard to the evaluation of the roadmap and as depicted in
Figure 6, organization ‘A’ neither agreed or disagreed that the
overview section was easy to understand and suggested that some
form of color-coding would improve it and make it visually more
appealing. On reflection, the authors consider this to be a valid
point and so the overview is amended to highlight the SDLC, CM
and RM processes (in red) and also the adoption of the best
practices (in blue) through these processes. Additionally,
organization ‘A’ suggested that the ‘resource’ best practice should
come first and that the best practices should be given a priority
rating. However, textual information in the overview section
indicates that an organization should decide at an organization
level, or the project manager should decide at the project level
which of the traceability best practices to implement. Factors
which will influence these decisions will include the availability
of resources and how highly regarded traceability is within the
organization. Additionally, the roadmap recommends that the best
practices are implemented in the order presented in the roadmap
where possible. This order of implementation arose as a result of
the roadmap validation through expert review.
6. CONCLUSION
The results of implementing the TAIF within two medical device
organizations clearly indicate a significant improvement in almost
all traceability processes within both organizations, although none
of the processes improved to a level of 100% adherence, the
overriding reason given for this is resource issues (mostly time)
within the organizations. These resource issues are clearly outside
the scope of the TAIF.
An evaluation of the assessment experience and traceability
roadmap clearly indicates that both organizations found them to
be very useful, usable and generally providing an awareness,
knowledge and expertise in traceability that they did not
previously have. Additionally, both organizations considered that
the assessment provided them with guidance and real direction for
long term traceability improvement.
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